Akari Therapeutics raises $2.5M in registered direct offering and warrant issuance

Akari Therapeutics Plc

Gross proceeds of $2.5M from sale of 3,125,000 ADSs at $0.80 per ADS; Ladenburg Thalmann as placement agent.
Concurrent private placement: Series E (5-year) and Series F (30-month) warrants to purchase up to 3.125M ADSs each at $0.98 exercise price; exercisable upon shareholder approval.
Proceeds to fund working capital, general corporate purposes, and R&D; includes generating data on ADC payload AKTX-101 for SITC meeting.
Offering expected to close on or about October 16, 2025, subject to customary closing conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.